Last reviewed · How we verify

Glycotope GmbH — Portfolio Competitive Intelligence Brief

Glycotope GmbH pipeline: 0 marketed, 0 filed, 0 Phase 3, 3 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

0 marketed 0 filed 0 Phase 3 3 Phase 2 2 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

No leading-phase drugs tracked for this sponsor.

Therapeutic area mix

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

  1. Ahn-Gook Pharmaceuticals Co.,Ltd · 1 shared drug class
  2. Ain Shams Maternity Hospital · 1 shared drug class
  3. Assistance Publique - Hôpitaux de Paris · 1 shared drug class
  4. Azienda USL Modena · 1 shared drug class
  5. Bezmialem Vakif University · 1 shared drug class
  6. Brenda Cooper, MD · 1 shared drug class
  7. Bristol-Myers Squibb · 1 shared drug class
  8. AGUNCO Obstetrics and Gynecology Centre · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for Glycotope GmbH:

Cite this brief

Drug Landscape (2026). Glycotope GmbH — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/glycotope-gmbh. Accessed 2026-06-10.

Related